Atara biotherapeutics' ebvallo™ (tabelecleucel) receives european commission approval as first ever therapy for adults and children with ebv+ ptld

Thousand oaks, calif. & castres, france--( business wire )--atara biotherapeutics, inc. (nasdaq: atra) and pierre fabre today announced that the european commission (ec) has granted marketing authorization for ebvallo™ (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory epstein‑barr virus positive post‑transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
ATRA Ratings Summary
ATRA Quant Ranking